Nextcure Stock Price, News & Analysis

NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on cancer therapy development, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Thursday, April 10th, at 8:45 am ET.

Investors and interested parties can access a live audio webcast through the Investors section of NextCure's website. The presentation recording will remain available on the company's website for 30 days following the event.

NextCure (NXTC) has reported its full year 2024 financial results and provided key business updates. The company has completed cohort 1 of the Phase 1 trial for LNCB74, their B7-H4 ADC cancer therapeutic, in February 2025 and plans to initiate backfill cohorts in H2 2025.

Financial highlights include cash position of $68.6 million, expected to fund operations into H2 2026. The company reported a net loss of $55.7 million for 2024, improved from $62.7 million in 2023. R&D expenses decreased to $41.5 million from $47.9 million, while G&A expenses reduced to $15.7 million from $19.7 million.

In pipeline developments, NextCure received FDA acceptance for LNCB74's IND application in December 2024 and dosed first patient in January 2025. The company is also seeking partners for two preclinical non-oncology programs: NC181 for Alzheimer's disease and NC605 for osteogenesis imperfecta.

NextCure (NXTC) has announced the dosing of its first patient in a Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) designed to treat multiple cancers. This milestone follows the FDA's clearance of the Investigational New Drug application for LNCB74 in December 2024.

The study aims to evaluate the safety, tolerability, and preliminary anti-tumor activity of LNCB74, which is being developed in partnership with LigaChem Biosciences through a collaboration and co-development agreement.

NextCure announced the FDA's acceptance of an Investigational New Drug (IND) application for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) developed in partnership with LigaChem Biosciences. This acceptance allows NextCure to proceed with a Phase 1 clinical trial to evaluate LNCB74 as a treatment for multiple cancers.

The company's CEO, Michael Richman, highlighted that this milestone aligns with their focus on advancing their ADC program. The IND application was supported by preclinical data demonstrating LNCB74's differentiation from other B7-H4-targeting ADCs, suggesting potential transformative treatment outcomes for patients.

NextCure (Nasdaq: NXTC) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference in New York City. The clinical-stage biopharmaceutical company, focused on developing novel cancer therapies, will engage in a fireside chat on Thursday, December 5, at 12:00 pm ET.

The event will feature a live audio webcast accessible through the Investors section of NextCure's website. The presentation will remain archived on the company's website for 30 days following the event.

NextCure announced preclinical data showing that NC605, their anti-Siglec-15 antibody, enhanced quality bone generation with improved mechanical properties in mice with Osteogenesis Imperfecta (OI). The study used NP159, a surrogate antibody to NC605, at 20 mg/kg dosage. Key results showed 90% of male and 80% of female treated mice had no fractures, compared to 85% and 55% in control groups. Both sexes demonstrated increased trabecular and cortical tissue mineral density. Male mice specifically showed increased trabecular bone volume and cortical thickness, resulting in improved mechanical bone strength.

NextCure has provided a business update and reported its third-quarter 2024 financial results. The company is focusing on LNCB74 (B7-H4 ADC) with a planned IND submission by year-end and aims to advance into Phase 1 trials. NextCure's cash reserves of approximately $75 million are expected to fund operations into the second half of 2026. The NC410 combo trial showed encouraging results in ovarian cancer and CRC patients but will conclude as the company seeks a partner for further development. Financially, NextCure's cash and equivalents decreased from $108.3 million to $75.3 million in 2024, primarily due to operational expenses. R&D expenses dropped to $8.8 million from $11.0 million, and G&A expenses decreased to $3.7 million from $4.6 million. The net loss for the quarter was $11.5 million, down from $14.3 million in the same period in 2023.

NextCure (NXTC) presented preclinical data for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC), and additional biomarker data for NC410 combination therapy at SITC. LNCB74 showed promising results with strong anti-tumor activity in multiple tumor models and favorable safety profile, with IND filing expected by year-end. The NC410/pembrolizumab combination demonstrated clinical activity in MSS/MSI-L colorectal cancer patients, achieving 3 partial responses among 43 evaluable patients and disease control rates of 86% and 47% at 200mg and 100mg doses, respectively. Biomarker data supported NC410's mechanism of action in remodeling tumor microenvironment.

NextCure Inc (Nasdaq: NXTC) announced two presentations at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in Houston, TX from November 6-10, 2024. The company will present:

1. Pre-clinical data on LNCB74, a B7-H4 antibody-drug conjugate, in a poster session on November 8.

2. Biomarker data from the NC410 combination study with pembrolizumab in ICI-naïve MSS/MSI-L colorectal cancer, in a poster session on November 9.

These presentations showcase NextCure's ongoing research in novel cancer therapies, particularly in antibody-drug conjugates and combination immunotherapies.